• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双四氢异喹啉生物碱的合成策略演变。

Evolution of a Synthetic Strategy toward the Syntheses of Bis-tetrahydroisoquinoline Alkaloids.

机构信息

The Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.

出版信息

Acc Chem Res. 2024 Jul 2;57(13):1870-1884. doi: 10.1021/acs.accounts.4c00262. Epub 2024 Jun 14.

DOI:10.1021/acs.accounts.4c00262
PMID:38874438
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11223266/
Abstract

ConspectusThe bis-tetrahydroisoquinoline (bis-THIQ) natural products represent a medicinally important class of isoquinoline alkaloids that exhibit broad biological activities with particularly potent antitumor properties, as exemplified by the two U.S. FDA approved molecules trabectidin and lurbinectedin. Accordingly, other members within the bis-THIQ family have emerged as prime targets for synthetic chemists, aiming to innovate an orthogonal chemical production of these compounds. With the ability of these complementary strategies to reliably and predictably manipulate molecular structures with atomic precision, this should allow the preparation of synthetic derivatives not existing in nature as new drug leads in the development of novel medicines with desired biological functions.Beyond the biological perspective, bis-THIQ natural products also possess intricate and unique structures, serving as a source of intellectual stimulation for synthetic organic chemists. Within our laboratory, we have developed an integrated program that combines reaction development and target-directed synthesis, leveraging the architecturally complex molecular framework of bis-THIQ natural products as a driving force for the advancement of novel reaction methodologies. In this Account, we unveil our synthetic efforts in a comprehensive story, describing how our synthetic strategy toward bis-THIQ natural products, specifically jorunnamycin A and jorumycin, has evolved over the course of our studies through our key transformations comprising (a) the direct functionalization of isoquinoline -oxide to prepare the bis-isoquinoline (bis-IQ) intermediate, (b) the diastereoselective and enantioselective isoquinoline hydrogenation to forge the pentacyclic skeleton of the natural product, and (c) the late-stage oxygenation chemistry to adjust the oxidation states of the A- and E-rings. First, we detail our plan in utilizing the aryne annulation strategy to prepare isoquinoline fragments for the bis-THIQ molecules. Faced with unpromising results in the direct C-H functionalization of isoquinoline -oxide, we lay out in this Account our rationale behind the design of each isoquinoline coupling partner to overcome these challenges. Additionally, we reveal the inspiration for our hydrogenation system, the setup of our pseudo-high-throughput screening, and the extension of the developed hydrogenation protocols to other simplified isoquinolines.In the context of non-natural bis-THIQ molecules, we have successfully adapted this tandem coupling/hydrogenation approach in the preparation of perfluorinated bis-THIQs, representing the first set of electron-deficient non-natural analogues. Finally, we include our unsuccessful late-stage oxygenation attempts prior to the discovery of the Pd-catalyzed C-O cross-coupling reaction. With this full disclosure of the chemistry developed for the syntheses of bis-THIQs, we hope our orthogonal synthetic tactics will provide useful information and serve as an inspiration for the future development of bis-THIQ pharmaceuticals.

摘要

概要双四氢异喹啉(双-THIQ)天然产物代表了一类具有重要医学意义的异喹啉生物碱,具有广泛的生物活性,特别是具有很强的抗肿瘤特性,美国食品和药物管理局批准的两种分子 trabectidin 和 lurbinectedin 就是例证。因此,双-THIQ 家族的其他成员已成为合成化学家的主要目标,旨在创新这些化合物的正交化学生产。这些互补策略能够以原子精度可靠且可预测地操纵分子结构,这应该允许制备自然界中不存在的合成衍生物,作为具有所需生物学功能的新型药物的新药物先导。

除了生物学角度外,双-THIQ 天然产物还具有复杂而独特的结构,为合成有机化学家提供了灵感来源。在我们的实验室中,我们开发了一个集成的计划,该计划结合了反应开发和靶向合成,利用双-THIQ 天然产物的架构复杂的分子框架作为推进新反应方法的驱动力。在本报告中,我们全面介绍了我们的合成工作,描述了我们的合成策略如何通过我们的关键转化(a)直接官能化异喹啉-氧化物以制备双异喹啉(双-IQ)中间体,(b)对映选择性异喹啉氢化以形成天然产物的五环骨架,以及(c)后期的氧化化学来调整 A-和 E-环的氧化态,在我们的研究过程中针对双-THIQ 天然产物(特别是jorunnamycin A 和 jorumycin)不断发展。首先,我们详细介绍了利用芳炔环加成策略制备双-THIQ 分子的异喹啉片段的计划。在直接 C-H 官能化异喹啉-氧化物方面遇到了不理想的结果,我们在本报告中详细说明了每个异喹啉偶联伙伴的设计背后的原理,以克服这些挑战。此外,我们还揭示了我们的氢化系统的灵感来源,伪高通量筛选的设置以及开发的氢化方案在其他简化异喹啉中的扩展。

在非天然双-THIQ 分子的背景下,我们成功地将这种串联偶联/氢化方法应用于全氟双-THIQ 的制备中,这是第一组电子缺电子的非天然类似物。最后,我们包括在发现 Pd 催化的 C-O 交叉偶联反应之前我们不成功的后期氧化尝试。通过全面披露用于双-THIQ 合成的化学,我们希望我们的正交合成策略将提供有用的信息,并为双-THIQ 药物的未来发展提供灵感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/e857b5ae45e5/ar4c00262_0023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/838d6b686051/ar4c00262_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/ff79fd46baca/ar4c00262_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/7453f28efeb8/ar4c00262_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/d1155be4ad30/ar4c00262_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/a648a695b840/ar4c00262_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/e5e160b362d6/ar4c00262_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/80af9395adb2/ar4c00262_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/ba90ca13aea7/ar4c00262_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/8a38dea9d7e1/ar4c00262_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/eb7f6f2fe58e/ar4c00262_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/cdf48c0bf171/ar4c00262_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/934a12df56c5/ar4c00262_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/c5e5023422f1/ar4c00262_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/429a947dbe14/ar4c00262_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/91c2bd24ec84/ar4c00262_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/1a4bf8a47b65/ar4c00262_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/b110949612a7/ar4c00262_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/c35d645bdf71/ar4c00262_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/2d37e417cc4b/ar4c00262_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/d98916bfba00/ar4c00262_0020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/cc188f3b4604/ar4c00262_0021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/50805c1017a3/ar4c00262_0022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/e857b5ae45e5/ar4c00262_0023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/838d6b686051/ar4c00262_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/ff79fd46baca/ar4c00262_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/7453f28efeb8/ar4c00262_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/d1155be4ad30/ar4c00262_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/a648a695b840/ar4c00262_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/e5e160b362d6/ar4c00262_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/80af9395adb2/ar4c00262_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/ba90ca13aea7/ar4c00262_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/8a38dea9d7e1/ar4c00262_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/eb7f6f2fe58e/ar4c00262_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/cdf48c0bf171/ar4c00262_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/934a12df56c5/ar4c00262_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/c5e5023422f1/ar4c00262_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/429a947dbe14/ar4c00262_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/91c2bd24ec84/ar4c00262_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/1a4bf8a47b65/ar4c00262_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/b110949612a7/ar4c00262_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/c35d645bdf71/ar4c00262_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/2d37e417cc4b/ar4c00262_0019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/d98916bfba00/ar4c00262_0020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/cc188f3b4604/ar4c00262_0021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/50805c1017a3/ar4c00262_0022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea54/11223266/e857b5ae45e5/ar4c00262_0023.jpg

相似文献

1
Evolution of a Synthetic Strategy toward the Syntheses of Bis-tetrahydroisoquinoline Alkaloids.双四氢异喹啉生物碱的合成策略演变。
Acc Chem Res. 2024 Jul 2;57(13):1870-1884. doi: 10.1021/acs.accounts.4c00262. Epub 2024 Jun 14.
2
Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis.不对称催化实现了(-)-jorunnamycin A 和(-)-jorumycin 的简洁全合成。
Science. 2019 Jan 18;363(6424):270-275. doi: 10.1126/science.aav3421. Epub 2018 Dec 20.
3
Progress in the Total Synthesis of Antitumor Tetrahydroisoquinoline Alkaloids.抗肿瘤四氢异喹啉生物碱全合成研究进展。
Chem Biodivers. 2023 May;20(5):e202300172. doi: 10.1002/cbdv.202300172. Epub 2023 Apr 4.
4
Recent Advances in the Total Synthesis of the Tetrahydroisoquinoline Alkaloids (2002-2020).四氢异喹啉生物碱的全合成研究进展(2002-2020)。
Chem Rev. 2023 Aug 9;123(15):9447-9496. doi: 10.1021/acs.chemrev.3c00054. Epub 2023 Jul 10.
5
New Strategies in the Efficient Total Syntheses of Polycyclic Natural Products.多环天然产物高效全合成的新策略。
Acc Chem Res. 2020 Nov 17;53(11):2569-2586. doi: 10.1021/acs.accounts.0c00531. Epub 2020 Nov 2.
6
A yeast platform for high-level synthesis of tetrahydroisoquinoline alkaloids.酵母平台用于四氢异喹啉生物碱的高水平合成。
Nat Commun. 2020 Jul 3;11(1):3337. doi: 10.1038/s41467-020-17172-x.
7
Biological activities of selected 1-Oxo-tetrahydroisoquinolinone alkaloids.所选1-氧代-四氢异喹啉酮生物碱的生物活性。
Nat Prod Res. 2025 Mar;39(6):1658-1671. doi: 10.1080/14786419.2024.2380008. Epub 2024 Jul 19.
8
Total synthesis of zoanthamine alkaloids.獐牙菜苦苷类生物碱的全合成。
Acc Chem Res. 2012 May 15;45(5):746-55. doi: 10.1021/ar200267a. Epub 2012 Feb 16.
9
In Pursuit of Synthetic Efficiency: Convergent Approaches.追求合成效率:汇聚方法。
Acc Chem Res. 2021 Feb 2;54(3):569-582. doi: 10.1021/acs.accounts.0c00727. Epub 2021 Jan 15.
10
Synthesis of Three-Dimensionally Fascinating Diterpenoid Alkaloids and Related Diterpenes.三维迷人的二萜生物碱和相关二萜的合成。
Acc Chem Res. 2021 Jan 5;54(1):22-34. doi: 10.1021/acs.accounts.0c00720. Epub 2020 Dec 22.

引用本文的文献

1
Cerium(III) immobilized on the functionalized halloysite as a highly efficient catalyst for aza-Diels-Alder reaction.负载于功能化埃洛石上的铈(III)作为氮杂-狄尔斯-阿尔德反应的高效催化剂。
Sci Rep. 2024 Nov 30;14(1):29772. doi: 10.1038/s41598-024-76775-2.

本文引用的文献

1
Recent Advances in the Total Synthesis of the Tetrahydroisoquinoline Alkaloids (2002-2020).四氢异喹啉生物碱的全合成研究进展(2002-2020)。
Chem Rev. 2023 Aug 9;123(15):9447-9496. doi: 10.1021/acs.chemrev.3c00054. Epub 2023 Jul 10.
2
Iridium-catalyzed asymmetric -selective hydrogenation of 1,3-disubstituted isoquinolines.铱催化的1,3-二取代异喹啉的不对称选择性氢化反应。
Chem Sci. 2022 Feb 18;13(11):3227-3232. doi: 10.1039/d1sc06729j. eCollection 2022 Mar 16.
3
Iridium-Catalyzed Enantioselective and Diastereoselective Hydrogenation of 1,3-Disubstituted Isoquinolines.
铱催化的1,3-二取代异喹啉的对映选择性和非对映选择性氢化反应
ACS Catal. 2020 Mar 6;10(5):3241-3248. doi: 10.1021/acscatal.0c00211. Epub 2020 Feb 10.
4
Chemical Research on Antitumor Isoquinoline Marine Natural Products and Related Compounds.抗肿瘤异喹啉海洋天然产物及相关化合物的化学研究。
Chem Pharm Bull (Tokyo). 2021;69(2):155-177. doi: 10.1248/cpb.c20-00820.
5
Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis.不对称催化实现了(-)-jorunnamycin A 和(-)-jorumycin 的简洁全合成。
Science. 2019 Jan 18;363(6424):270-275. doi: 10.1126/science.aav3421. Epub 2018 Dec 20.
6
Chemo-enzymatic Total Syntheses of Jorunnamycin A, Saframycin A, and N-Fmoc Saframycin Y3.乔鲁那霉素 A、沙福菌素 A 和 N-Fmoc 沙福菌素 Y3 的化学-酶全合成。
J Am Chem Soc. 2018 Aug 29;140(34):10705-10709. doi: 10.1021/jacs.8b07161. Epub 2018 Aug 16.
7
Strong Brønsted acid promoted asymmetric hydrogenation of isoquinolines and quinolines catalyzed by a Rh-thiourea chiral phosphine complex anion binding.强布朗斯特酸促进的铑-硫脲手性膦配合物催化的异喹啉和喹啉的不对称氢化反应 阴离子结合作用
Chem Sci. 2016 May 1;7(5):3047-3051. doi: 10.1039/c5sc04712a. Epub 2016 Jan 26.
8
Synthesis of Complex Phenols Enabled by a Rationally Designed Hydroxide Surrogate.通过合理设计的氢氧化物替身物实现复杂酚类的合成。
Angew Chem Int Ed Engl. 2017 Apr 10;56(16):4478-4482. doi: 10.1002/anie.201700244. Epub 2017 Mar 24.
9
Dirhodium-catalyzed C-H arene amination using hydroxylamines.使用羟胺的二铑催化的C-H芳烃胺化反应
Science. 2016 Sep 9;353(6304):1144-7. doi: 10.1126/science.aaf8713.
10
Stereoselective Total Synthesis of (-)-Renieramycin T.(-)-雷尼霉素 T 的立体选择性全合成。
J Org Chem. 2016 May 20;81(10):4039-47. doi: 10.1021/acs.joc.6b00327. Epub 2016 May 3.